Screener
Ultragenyx Pharmaceutical RARE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's cash & equivalents?
- Ultragenyx Pharmaceutical (RARE) reported cash & equivalents of $125M in Q2 2026.
- How has Ultragenyx Pharmaceutical's cash & equivalents changed year-over-year?
- Ultragenyx Pharmaceutical's cash & equivalents decreased by 29.0% year-over-year, from $176M to $125M.
- What is the long-term trend for Ultragenyx Pharmaceutical's cash & equivalents?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's cash & equivalents has grown at a -10.0% compound annual growth rate (CAGR), from $713.53M to $421M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Ultragenyx Pharmaceutical's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude